Purpose: ''Statins'' have immunomodulatory and anti-inflammatory effects and may attenuate the risk of infections. We sought to determine the association between chronic statin use and long-term rates of sepsis events. Materials and Methods: We used data from 30 183 adult (!45 years old) community-dwelling participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. The primary exposure was statin use. The primary outcome was hospitalization or emergency department treatment for sepsis. Using Cox proportional hazards models, we determined associations between statin use and first sepsis events, adjusting for patients demographics, health behaviors, chronic medical conditions, degree of medication adherence, baseline high-sensitivity C-reactive protein (hsCRP), and propensity for statin use. Results: Approximately one-third of participants reported statin use (n ¼ 9475, 31.4%). During the 10-year follow-up period from 2003 to 2012, there were 1500 incident sepsis events. Statin use was not associated with rates of sepsis after multivariable adjustment for demographics, health behaviors, chronic medical conditions, medication adherence, abnormal hsCRP, and propensity for statin use, hazard ratio 0.93 (95% confidence interval: 0.81-1.06). Statin use was not similarly associated with rates of sepsis when stratified by propensity for statin use or medication adherence. Conclusion: In the REGARDS cohort, statin use at baseline was not associated with rates of future sepsis events.
Introduction
Sepsis, the syndrome of microbial infection complicated by systemic inflammation, is a major public health problem associated with significant morbidity and mortality. 1 The substantial national burden of severe sepsis care in the United States encompasses 750 000 hospital admissions, 570 000 emergency department visits, 200 000 deaths, and US$16.7 billion in medical expenditures annually. [2] [3] [4] Originally developed to reduce cholesterol levels, 3hydroxy-3-methylglutaryl-CoA reductase inhibitors (''statins'') also appear to modulate immune response and attenuate the pathophysiologic responses of sepsis. [5] [6] [7] [8] [9] [10] These findings have led to the hypothesis that statins may exert a protective effect in patients with infections or sepsis. For example, statin users admitted to the hospital for acute infections exhibit reduced morbidity and mortality compared with nonstatin users. 5, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 25 However, these prior studies have focused exclusively on acutely ill individuals and the use of statins as a form of secondary prevention or acute therapy to mitigate the progression of sepsis. There have been few examinations of the influence of chronic statin use on long-term communityacquired sepsis susceptibility in healthy individuals. Such an association would suggest a potential role for chronic statin use in the primary prevention of sepsis.
The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study is one of the largest populationbased cohorts of community-dwelling individuals in the United States. 23 In this study, we sought to determine the association between chronic statin use and long-term rates of sepsis events in the REGARDS cohort.
Methods

Study Design
We utilized data from the longitudinal population-based REGARDS cohort. The study received approval by the institutional review board of the University of Alabama at Birmingham.
Identification of Sepsis Events
Using published taxonomies, we identified all hospitalizations and emergency department visits attributed by participants to a serious infection. 2, 3 Two abstractors independently reviewed all relevant medical records to confirm the presence of a serious infection on initial hospital presentation. The abstractors also confirmed that the serious infection was a major reason for hospitalization. Discordances were resolved by abstractor consensus, with additional physician-level review as needed.
We defined sepsis as presentation to the hospital with an infection plus 2 or more systemic inflammatory response syndrome criteria, including (1) heart rate >90 beats/min, (2) fever (temperature >38.3 C or <36 C), (3) tachypnea (>20 breaths/min), or PCO 2 < 32 mm Hg, and (4) leukocytosis (white blood cells > 12 000 or <4 000 cells/mm 3 or >10% band forms). We examined vital signs and laboratory test results for the initial 28 hours of hospitalization to encompass emergency department care and up to 1 full day of inpatient treatment. Because of our focus on ''community-acquired'' sepsis, we did not examine vital signs or laboratory findings from later time points or sepsis developing at later phases of hospitalization. Initial review of 1349 hospital records indicated excellent interrater agreement for presence of a serious infection (k ¼ .92) and the presence of sepsis (k ¼ .90) upon hospital presentation.
We did not include organ dysfunction in the primary definition of sepsis. However, in the sensitivity analysis, we did examine the secondary outcome, that is, severe sepsis defined as sepsis þ organ dysfunction. We also studied sepsis hospital death, defined as death after sepsis hospitalization.
Covariates: Definition of Statin Use
At the initial interview, REGARDS obtained an inventory of all medications used by the participants. Specific statins reported by patients included atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. The study did not account for changes in medication patterns over time.
Other covariates examined in the study included sociodemographic characteristics, health behaviors, chronic medical conditions, baseline high-sensitivity C-reactive protein (hsCRP), and the Morisky Medication Adherence Scale. Sociodemographic characteristics included age, sex, race, geographic region, self-reported annual household income, and selfreported education (years of school). Geographic region included participant residence in the stroke buckle, stroke belt, and elsewhere as defined for the REGARDS recruitment sampling strategy. 23 Health behaviors included tobacco and alcohol use. Smoking status included current, past, and never. Based upon National Institute on Alcohol Abuse and Alcoholism classifications, alcohol use included none, moderate (1 drink per day for women or 2 drinks per day for men), and heavy (>1 drink per day for women and >2 drinks per day for men). 24 The evaluated chronic medical conditions included history of obesity, diabetes, dyslipidemia, hypertension, stroke, myocardial infarction, coronary artery disease, atrial fibrillation, deep vein thrombosis, peripheral artery disease, chronic kidney disease, and chronic lung disease. We defined obesity as participants with large waist circumference (WC) or obese body mass index (BMI). Weight, height, and WC were measured during initial patient examination at the beginning of the REGARDS study. Calculated as weight/height 2 (kg/m 2 ), we categorized BMI as underweight (<18.5 kg/m 2 ), normal (18.5-25 .0 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), obese (30-39.9 kg/m 2 ), and morbidly obese (!40 kg/m 2 ). 26 Determined with the patient in standing position, WC was measured midway between the lowest rib and the iliac crest, with normal WC defined as 102 cm for males and 88 cm for females and large WC as >102 cm for males and >88 cm for females. 27 Diabetes included a fasting glucose of !126 mg/L (or a glucose !200 mg/L for those not fasting) or the use of insulin or oral hypoglycemic agents. Dyslipidemia included individuals with self-reported high cholesterol or the use of lipidlowering medications. Hypertension consisted of systolic blood pressure !140 mm Hg, diastolic blood pressure !90 mm Hg, or the self-reported use of antihypertensive agents. Stroke consisted of the self-reported history of stroke. Myocardial infarction included individuals with a self-reported history of myocardial infarction or baseline electrocardiographic evidence of myocardial infarction. Coronary artery disease consisted of individuals with a self-reported history of myocardial infarction, coronary intervention, or baseline electrocardiographic evidence of myocardial infarction.
Chronic kidney disease consisted of an estimated glomerular filtration rate of <60 ml/min/1.73m 2 . 28 Because REGARDS did not collect information on pulmonary conditions such as asthma and chronic obstructive pulmonary disease, we considered participant's use of pulmonary medications as a surrogate for chronic lung disease. Obtained from each participant's medication inventory, pulmonary medications included b agonists, leukotriene inhibitors, inhaled corticosteroids, combination inhalers, and other pulmonary medications such as ipratropium, cromolyn, aminophylline, and theophylline.
High-sensitivity CRP was determined by particle-enhanced immunonephelometry. In contrast with conventional CRP assays, the hsCRP technique is able to detect levels as low as 0.04 mg/L. Consistent with prior cardiovascular studies, we defined elevated baseline hsCRP as >3.0 mg/L. 29 We previously identified an association between baseline hsCRP and rates of sepsis. 30 For sepsis hospitalizations, we identified organ dysfunctions using the Sequential Organ Failure Assessment using the worst laboratory and physiologic findings during the first 28 hours of hospitalization for respiratory, renal, hepatic, cardiovascular, hematologic, and neurologic systems. 31 During initial interview for the REGARDS study, participants reported medication adherence using the 4-question version of the Morisky Medication Adherence Scale, which provides a measure of individual compliance with medication use 32 (Appendix A). We defined medication adherence as 0 ¼ good, 1 ¼ fair, and 2 to 4 ¼ poor.
Data Analysis
We compared differences in participant baseline characteristics between baseline statin users and nonusers using the chi-square test. Although individual statin use is influenced by cardiovascular risk, past reports suggest that statin users in general are healthier than nonusers. 33, 34 Observational studies may therefore find apparent protective effects of statins that may reflect the healthier nature of statin users relative to nonusers (''healthy user effect'') and not true statin effects per se. 35 Because of this likely influence in the present study, we defined a propensity score to reflect the propensity for baseline statin use for each study patient. 36, 37 We calculated the propensity score using the ''pscore'' module of Stata, specifying a logit model. Initial efforts using an unparsimonious model with all defined clinical covariates failed to satisfy the balancing property. 36 However, a propensity score based upon obesity, dyslipidemia, diabetes, myocardial infarction, and elevated hsCRP satisfied the balancing property.
We conceptualized that the association between baseline statin use and rates of sepsis may be influenced by the participant's propensity for statin use, demographics, health behaviors, chronic medical conditions, degree of medication adherence, and baseline hsCRP. We therefore fit a sequence of multivariable Cox proportional hazards models examining the association of baseline statin use with risk of first sepsis event, sequentially adjusting for each of the relevant covariates. Because they were used for propensity score estimation, we excluded obesity, diabetes, hypercholesterolemia, history of myocardial infarction, and abnormal hsCRP from the multivariable models. We censored participants who died before their first sepsis event or who were lost to follow-up. We excluded individuals with missing outcome, exposure, or confounder values.
To verify the robustness of the findings, we repeated the analysis stratifying by propensity score tertiles (corresponding to low, medium, and high propensity for statin use). 36, [38] [39] [40] We also repeated the analysis stratified by categories of Morisky medication adherence (0, 1, and 2-4, corresponding to good, fair, and poor medication adherence, respectively). We verified the proportional hazard assumption by examining log-log and observed versus predicted survival plots, testing Schoenfeld residuals and fitting a model with statin use as a time-varying covariate. We verified the absence of collinearities by examining variance inflation factors.
Many studies have evaluated the association between statin use and the severity or mortality after sepsis. 16, 17, 19, 20, [41] [42] [43] [44] In a sensitivity analysis of sepsis hospitalizations only, we examined the association between statin use and (1) severe sepsis and (2) hospital death after sepsis. We conducted the sensitivity analysis using multivariable logistic regression, adjusting for participant's propensity for statin use, demographics, health behaviors, chronic medical conditions, degree of medication adherence, baseline hsCRP, and Mortality of Emergency Department Sepsis (MEDS) score. 45 We performed the analysis using Stata v.12.1 (Stata Inc, College Station, Texas).
Results
From February 5, 2003, through December 31, 2012, among the 30 183 REGARDS participants included in the analysis, a total of 1500 individuals experienced a sepsis event; of these first sepsis events, 1089 (72.6%) met severe sepsis criteria and 138 (9.2%) resulted in hospital death (Figure 1 ). Median follow-up time was 6.6 years (interquartile range 5.1-8.1 years). Among the first sepsis events, the most common infection types were pneumonia, kidney and urinary tract infections, and abdominal infections (Table 1) .
Approximately, one-third of REGARDS participants were baseline statin users (n ¼ 9475, 31.4%). Statin users were more likely to be older, female, and white ( Table 2) . Although statin users were more likely to have chronic medical conditions, they were less likely to have elevated hsCRP (>3.0 mg/dL). Statin users reported higher Morisky medication adherence.
Overall, the cohort accounted for 186 420 person-years and 1498 first sepsis events (sepsis incidence ¼ 8.0 per 1000 person-years, 95% confidence interval [CI]: 7.6-8.5; Figure  2 ). Statin users accounted for 58 412 person-years and 552 first sepsis events (incidence 9.5 per 1000 person-years, 95% CI: 8.7-10.3), and nonstatin users accounted for 128 008 personyears and 946 first sepsis events (incidence 7.4 per 1000 person-years, 95% CI: 6.9-7.9).
On bivariate analysis, baseline statin use was associated with increased risk of first sepsis events (Table 3 ). However, statin use was no longer associated with rates of sepsis after multivariable adjustment for propensity score, demographics, health behaviors, chronic medical conditions, abnormal hsCRP, and medication adherence (adjusted hazard ratio [HR] 0.93; 95% CI: 0.81-1.06). Multiplicative (statin Â propensity score) and (statin Â Morisky Scale) interactions were not statistically significant. When stratified by propensity score tertile, statin use was not associated with rates of sepsis after adjustment for confounders. Although not associated with rates of sepsis for individuals with fair or poor medication adherence, statin use showed a tendency toward a protective effect in the subgroup with good medication adherence.
Among first sepsis hospitalizations, the presence of severe sepsis was not associated with statin use after adjustment for confounders and MEDS score (odds ratio [OR] 1.34; 95% CI: 0.95-1.90). Hospital death after sepsis was not associated with statin use, after adjustment for confounders and MEDS score (OR 0.72; 95% CI: 0.42-1.23). 
REGARDS
Discussion
Based upon data from a large population-based cohort of community dwelling adults in the United States, we found that baseline statin use was not associated with the long-term rates of future sepsis events. This observation persisted after adjustment for a host of clinical confounders, including propensity for statin use as well as medication adherence. Furthermore, among first sepsis events, statin use was not associated with the presence of severe sepsis or sepsis hospital death. To understand the importance and novelty of these findings, one must understand the following 3 potential roles for statins in sepsis treatment: (1) primary prevention (preventing an individual from acquiring sepsis), (2) secondary prevention (continuation of statin use in acutely ill individuals to limit progression to severe sepsis or death), and (3) acute treatment (initiation of statin use to reduce sepsis-induced morbidity and mortality). 46 Our study clearly falls into the primary prevention category. However, in contrast to other studies of primary sepsis prevention, our unique study was able to characterize the association of baseline chronic statin use with long-term rates of communityacquired sepsis in healthy community-dwelling adults. Mermis and Simpson provide a comprehensive review of the role of statins in sepsis treatment and prevention. 46 Most studies characterized as primary prevention efforts (1) have been retrospective, (2) included only intensive care unit or hospitalized inpatients, and (3) focused on sepsis progression or mortality as end points. [16] [17] [18] [19] [20] 22, 25, 47, [41] [42] [43] [44] Furthermore, these studies characterized statin use retrospectively, hence addressing ''current'' statin use versus ''chronic'' statin use evaluated in our study. For example, Murugan et al and Yende et al studied 1895 patients hospitalized for community-acquired pneumonia, finding no association between prior statin use (reported by the patient) and 90-day survival or rates of acute kidney injury. 18, 41 In a study of 121 254 inpatients with pneumonia, Rothberg et al found that statin use was associated with reduced mortality, but statin use was defined as drug administration on day 1 or 2 of hospitalization. 16 Although our primary analysis focused on susceptibility to community-acquired sepsis, in secondary analyses limited to first sepsis hospitalizations, we found no association between chronic statin use and severe sepsis or hospital death.
Select studies do have closer resemblance to our analysis. Gupta et al prospectively studied a cohort of 1041 patients who underwent dialysis in the United States Renal Data System; over a mean follow-up period of 3.4 years, statin users were less likely to be hospitalized for sepsis (HR 0.38; 95% CI: 0.21-0.67). 48 Using claims data from Ontario, Canada, Hackam et al studied 69 168 individuals hospitalized for acute coronary syndrome, ischemic stroke, or revascularization; over a mean follow-up period of almost 4 years, rates of sepsis were lower for statin users than nonusers (HR 0.81; 95% CI: 0.72-0.90). 49 The JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) trial randomized 18 802 individuals to statins or placebo; in a 2-year follow-up of trial participants, Novack et al found that the risk of pneumonia was lower among those randomized to rosuvastatin (HR 0.81; 95% CI 0.67-0.97); however, infections were identified from adverse event reports, not active surveillance. 47, 50 Our analysis has important contrasts with these prior studies. The REGARDS is a large population-based cohort of community-dwelling adults. Our study was not limited to individuals admitted to the hospital or to cohorts with significant comorbidities such as end-stage renal disease. We were able to follow patients for over 10 years, exceeding the observation period of the prior studies. Unlike the Novack et al study, we examined a range of sepsis events-not just pneumonia. 47 We also identified sepsis events through prospective review of medical records; we did not rely upon hospital discharge diagnoses to identify sepsis events. Observational studies of medication usage and outcomes may be influenced by confounding by indication or ''healthy user'' effects. 37 Unlike the prior studies, we were better able to account for propensity for statin use as well as medication adherence.
Could statin use still play a role in reducing rates of sepsis? In our prior efforts, we have found that rates of sepsis are associated with a host of cardiovascular medical conditions, including diabetes, coronary artery disease, dyslipidemia, and atrial fibrillation. 51, 52 It is possible that statins may indirectly reduce rates of sepsis by mediating the adverse influences of these related factors. We observed that statin use did show a slight tendency toward reduced rates of sepsis in the subgroup reporting good medication adherence. If additional studies were to confirm the protective effect of statins against sepsis, we would expect this association to be more prominent among those demonstrating good medication compliance. Additional studies must clarify this relationship. 
Limitations
Our analysis assumed that REGARDS participants continued statin use throughout the entire 10-year follow-up period. However, statin use may have varied over time, with select individuals ceasing-or initiating-the medication. These potential misclassifications may have led to over-or underestimates of the protective effects of statin use. Because of the design of the study, we could not ascertain changes in statin use over time.
However, REGARDS is one of the few cohorts with the design necessary to evaluate the long-term risk of sepsis associated with chronic statin use, and thus our study reflects the best data currently available. Other studies have retrospectively identified statin use on hospital admission, but this approach does not allow evaluation of the long-term effects of long-term statin use. We tried to mitigate the effects of statin misclassification by controlling for medication adherence. REGARDS is in the process of reinterviewing all participants, and thus in the future, it may be possible to ascertain changes in statin use in the cohort. Although we applied numerous analytic strategies to compensate for confounding by indication, there may be unmeasured or immeasurable confounders related to statin use. 37, 53 While the multivariable models indicate a range of characteristics associated with sepsis susceptibility, in this analysis, these covariates were intended for risk adjustment only. Identification of subject characteristics independently associated with sepsis is beyond the scope of this analysis.
By design, the REGARDS cohort includes only African Americans and whites, and thus these results may not generalize to other ethnic groups. We did not examine the association between statin use and sepsis in racial or geographic subgroups. Also, our study was able to detect the presence of chronic medical conditions but not their level of severity. The data do not have information on history of immunocompromise. We focused on community-acquired sepsis-our study did not evaluate sepsis developing at later points of hospitalization. Although a small portion of patients received emergency department treatment only (without hospital admission), we verified through review of medical records that all of these individuals fulfilled sepsis criteria. Although some variables had missing values, the frequency of missing was relatively limited. Because REGARDS is not a surveillance study, we may not have detected all sepsis events.
Conclusion
In this large national cohort of community-dwelling adults, baseline statin use was not associated with long-term rates of sepsis. and all authors contributed to its editorial review and revision. HEW assumes responsibility for the work as a whole. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Representatives of the funding agencies have been involved in the review of the manuscript but not directly involved in the collection, management, analysis, or interpretation of the data.
Appendix A Elements of the 4-item Morisky Medication Adherence Scale
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